Autoimmune post-COVID vaccine syndromes: Does the spectrum of autoimmune/inflammatory syndrome expand

Basit Öğe Kaydı
dc.authorid0000-0002-7919-1326
dc.contributor.authorJara, Luis Javier
dc.contributor.authorVera-Lastra, Olga
dc.contributor.authorMahroum, Naim
dc.contributor.authorPineda, Carlos
dc.contributor.authorShoenfeld, Yehuda
dc.date.accessioned2022-11-15T12:02:39Z
dc.date.available2022-11-15T12:02:39Z
dc.date.issued2022
dc.departmentİstanbul Medipol Üniversitesi, Uluslararası Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractTo date, around 60% of the world population has been protected by vaccines against SARS-CoV-2, significantly reducing the devastating effect of the pandemic and restoring social economic activity through mass vaccination. Multiple studies have demonstrated the effectiveness and safety of vaccines against COVID-19 in healthy populations, in people with risk factors, in people with or without SARS-CoV-2 infection, and in immunocompromised people. According to the criteria for post-vaccine adverse events established by the World Health Organization, a minority of individuals may develop adverse events, including autoimmune syndromes. The exact mechanisms for the development of these autoimmune syndromes are under study, and to date, a cause-effect relationship has not been established. Many of these autoimmune syndromes meet sufficient criteria for the diagnosis of Adjuvant-Induced Autoimmune Syndrome (ASIA syndrome). The descriptions of these autoimmune syndromes open new perspectives to the knowledge of the complex relationship between the host, its immune system, with the new vaccines and the development of new-onset autoimmune syndromes. Fortunately, most of these autoimmune syndromes are easily controlled with steroids and other immunomodulatory medications and are short-lived. Rheumatologists must be alert to the development of these autoimmune syndromes, and investigate the relationship between autoimmune/inflammatory symptoms and vaccination time, and assess their therapeutic response.
dc.identifier.citationJara, L. J., Vera-Lastra, O., Mahroum, N., Pineda, C. ve Shoenfeld, Y. (2022). Autoimmune post-COVID vaccine syndromes: Does the spectrum of autoimmune/inflammatory syndrome expand. Clinical Rheumatology, 41(5), 1603-1609. https://doi.org/10.1007/s10067-022-06149-4
dc.identifier.doi10.1007/s10067-022-06149-4
dc.identifier.endpage1609
dc.identifier.issn0770-3198
dc.identifier.issn1434-9949
dc.identifier.issue5
dc.identifier.pmid35378658
dc.identifier.scopus2-s2.0-85127606959
dc.identifier.scopusqualityQ1
dc.identifier.startpage1603
dc.identifier.urihttps://doi.org/10.1007/s10067-022-06149-4
dc.identifier.urihttps://hdl.handle.net/20.500.12511/9965
dc.identifier.volume41
dc.identifier.wos000778087400001en_US
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorMahroum, Naim
dc.language.isoen
dc.publisherSpringer London Ltd
dc.relation.ispartofClinical Rheumatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAdverse Event Vaccine
dc.subjectAutoimmune Diseases
dc.subjectAutoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA Syndrome)
dc.subjectAutoimmunity
dc.subjectCOVID-19 Vaccine
dc.titleAutoimmune post-COVID vaccine syndromes: Does the spectrum of autoimmune/inflammatory syndrome expand
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Mahroum-Naim-2022.pdf
Boyut:
694.61 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu